LONCASTUXIMAB TESIRINE
UNII 7K5O7P6QIU

Substance Identification & Data

This profile provides standardized clinical and technical data for Loncastuximab Tesirine, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 7K5O7P6QIU.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 1879918-31-6 and the RxNorm Concept ID (RxCUI) 2540964. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

7K5O7P6QIU

CAS Registry Number

1879918-31-6

RxNorm Concept ID

2540964

Detailed Substance Profile

Preferred Name

LONCASTUXIMAB TESIRINE

Official standardized name for this substance within the FDA UNII nomenclature system.

Molecular Formula

7K5O7P6QIU

The specific atomic composition represented as a molecular structure string.

NCI Thesaurus

C125549

National Cancer Institute reference terminology for clinical and research data.

INN ID

10586

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

FG-29

Identifier assigned by the United States Adopted Names Council.

Substance Type

protein

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Loncastuximab Tesirine. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

LONCASTUXIMAB TESIRINE

LONCASTUXIMAB TESIRINE-LPYL

Common Names & Synonyms

LONCASTUXIMAB TESIRINE [INN]

LONCASTUXIMAB TESIRINE [USAN]

LONCASTUXIMAB TESIRINE [WHO-DD]

LONCASTUXIMAB TESIRINE LPYL [WHO-DD]

Brand / Trade Names

ZYNLONTA

Systematic Nomenclature

IMMUNOGLOBULIN G1, ANTI-(HUMAN CD19 ANTIGEN) (HUMAN-MUS MUSCULUS MONOCLONAL RB4V1.2 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL RB4V1.2 .KAPPA.-CHAIN, DIMER, BIS(THIOETHER) WITH N-(31-(2,5-DIHYDRO-2,5-DIOXO-1H-PYRROL-1-YL)-1,29-DIOXO-4,7,10,13,16,19,22,25-OCTAOXA-28-AZAHENTRIACONT-1-YL)-L-VALYL-N-(4-(((((11S,11AS)-8-((5-(((11AS)-5,11A-DIHYDRO-7-METHOXY-2-METHYL-5-OXO-1H-PYRROLO(2,1-C)(1,4)BENZODIAZEPIN-8-YL)OXY)PENTYL)OXY)-11,11A-DIHYDRO-11-HYDROXY-7-METHOXY-2-METHYL-5-OXO-1H-PYRROLO(2,1-C)(1,4)BENZODIAZEPIN-10(5H)-YL)CARBONYL)OXY)METHYL)PHENYL)-L-ALANINAMIDE

SYS

IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS B-LYMPHOCYTE ANTIGEN CD-19)CHIMERIC MONOCLONAL ANTIBODY CONJUGATED TO AN AVERAGE OF TWO MOLECULES OF TESIRINE.GAMMA.1 HEAVY CHAIN (1-449) (MUS MUSCULUS VH (IGHV1-69*02 (86%) (IGHD)-IGHJ4*01)) (8.8.13) (1-120) -HOMO SAPIENS IGHG1*03 ((R97)CH1(K>R(217)),DES-K107CH3(K>-(250))), (121-249)) (223-211')-DISULFIDE WITH .KAPPA. LIGHT CHAIN (1'-211') (MUS MUSCULUS V-KAPPA (IGKV4-70*01 (91%) IGKJ1*01) (5.3.7) (1'-104') -HOMO SAPIENS IGKC*01 (105'-211')), DIMER (229-229'':232-232'')-BISDISULFIDE, AN AVERAGE OF TWO CYSTEINES ARE S-LINKED TO (111AS,911S,911AS,16S,19S,523RS)-911-HYDROXY-17, 97-DIMETHOXY-12,92,16-TRIMETHYL-15,95,10,15,18,21,49,522-525-NONAOXO-19-(PROPAN-2-YL)-15,111A,911,911A-TETRAHYDRO-11H,91H,95H-2,8,11,24,27,30,33,36,39,42,45-UNDECAOXA-14,17,20,48-TETRAAZA-1(8),9(8,10)-BIS(PYRROLO(2,1-C)(1,4)BENZODIAZEPINE)-52(1)-PYRROLIDINA-13(1,4)BENZENADOPENTACONTAPHAN-523-YL

SYS